Kelsy Ketchum

The firm's Q4 2024 overall revenues were up 7 percent and full-year 2024 revenues were up 5 percent.

The firm announced preliminary full-year 2024 revenue estimates that were slightly below expectations.

Although the firm did not provide preliminary financial results for 2024, CEO Chris Smith reaffirmed previous guidance of revenues between $655 million and $667 million.

Executives also provided additional information on the firm's Q4 2024 financial performance.

Boulud also provided additional information on the company's Q4 performance, noting that it placed 900 SpotFire point-of-care PCR instruments during the quarter.

The firm said preliminary core Q4 2024 revenues are expected to be flat, exceeding prior expectations, while its China business has stabilized and will recover.

The acquisition of genetic testing firm Ambry will open up new markets for Tempus, which is looking beyond the oncology field.

Brian Blaser said the firm has eliminated certain C-suite positions and implemented strategies to improve the firms profitability.

In 2024, there were 54 private financing deals in the diagnostics industry, compared to 43 in 2023.

Only 20 full-company mergers or acquisitions occurred throughout the year, although asset acquisition deals were more common.